In connection with the placement, DIAGNOS paid $39,246.72 in cash commissions and issued 130,821 finder’s warrants to five firms. These finder’s warrants allow the purchase of shares at $0.40 for 18 months. The securities are subject to a hold period until June 6, 2025, and the placement's closing is contingent on necessary approvals, including from the TSX Venture Exchange. DIAGNOS is known for its FLAIRE AI platform and CARA tool, which enhances retinal image analysis for patient screening.
Key takeaways:
- DIAGNOS Inc. closed a non-brokered private placement of 6,715,370 units at $0.30 per unit, raising $2,014,611.
- Each unit consists of one common share and one common share warrant, exercisable at $0.40 per share for 18 months.
- The net proceeds will fund AI-based screening services, regulatory affairs, and general operations.
- All securities issued are subject to a statutory hold period ending June 6, 2025.